LUNG CANCER

A More Personalized, Non-Surgical Treatment For Lung Cancer

Lung cancer treatment that revolves around you.

One of the biggest challenges in lung cancer treatment remains effectively treating the cancer, while minimizing dose to the many sensitive tissues and vital organs that surround the lungs. Precision is critical because the lungs are the center of a person’s respiratory system and play a key role in their ability to breathe. The Radixact® System provides the flexibility to adapt radiation therapy to any lung cancer patient’s anatomy. The system offers a non-surgical option for treating lung cancer designed to maximize the radiation delivered to the cancerous tumor while minimizing dose to healthy tissues. This precision helps to improve the effectiveness of the cancer treatment, while reducing the risk of side effects to protect your quality of life both during and after treatment.

The Radixact System, the next-generation TomoTherapy® platform, has been designed to enable doctors to more effectively and efficiently deliver precise radiation treatments to more patients. The TomoTherapy platform represented a dramatic advance in the radiation oncology field, as the only system specifically designed for integrated 3D daily image-guidance with intensity modulated radiation therapy (IG-IMRT) that will help you fight your cancer.

Key treatment benefits of the Radixact System using TomoTherapy technology

  • Non-surgical and non-invasive
  • Good cancer control
  • The radiation beams are shaped to closely fit the area of the cancer, helping to significantly reduce common side effects
  • Most patients can continue normal activity throughout treatment
  • Can be used in combination with chemotherapy and other medications

Ask a physician if Radixact treatment is right for you

You deserve the best possible treatment for your lung cancer. Find a physician in your area offering the Radixact System — and find out if Radixact treatment is right for you.

  • Clinically Proven Outcomes
  • Synchronized with Natural Breathing
  • A Non-Surgical Option
  • Enabling Re-Treatment
  • Radixact vs. Surgery

A clinically proven treatment for lung cancer

The Radixact System, the next-generation TomoTherapy platform, is one of the most integrated, advanced systems for comprehensive cancer treatment available today, enabling precise delivery of simple-to-complex treatments for the full spectrum of lung cancer patients — ranging from early-stage non-small cell lung cancer (NSCLC) to post-surgery treatment of mesothelioma. The TomoTherapy technology is supported by published clinical studies:

  • Early-stage non-small cell lung cancer (NSCLC): Lung SBRT with the TomoTherapy technology delivers good local control and survival with low toxicity in the treatment of early-stage non-small cell lung cancer.1
  • Medically inoperable lung cancer: Lung SBRT with the TomoTherapy technology provides a safe and effective alternative when surgery is not possible.2
  • Mesothelioma: IMRT with the TomoTherapy technology delivers excellent local-regional control and survival in the treatment of malignant pleural mesothelioma (MPM).3
  • Oligometastases: SBRT with the TomoTherapy technology delivers adequate local control with low acute morbidity in the treatment of oligometastases, including multiple metastases.4

Radixact tracks and targets your tumor in real-time

When you breathe, your torso moves. This means that a lung tumor — or any target in or near the lungs — will continuously move throughout the course of treatment delivery. Unlike any other conventional radiation devices, the Radixact System uses the world’s only real-time motion synchronization technology to continuously track the target, and automatically adapt and synchronize the radiation beam with movement of the target in real-time throughout the entire treatment session.* This helps to ensures the radiation dose is delivered to the target — maximizing treatment effectiveness while minimizing dose to surrounding tissues to reduce the incidence of side effects. And unlike other conventional radiotherapy options, the Radixact System does not require uncomfortable patient restraints or inefficient gating techniques. You can relax and breathe normally.

*The Synchrony technology is an optional upgrade available for purchase by hospitals.

A non-invasive, non-surgical option

While surgery is often considered the gold standard of treatment, its application may be limited by the patient’s health and the stage and location of the tumor. Treatments with the Radixact System are completely non-surgical, non-invasive and pain-free. This makes the Radixact System a good treatment option when more invasive techniques are deemed inappropriate or too risky. Radixact treatment may also be an option in cases where patients cannot undergo surgical procedures as a result of:

  • Location or size of the tumor
  • Patient's health
  • Previous surgery or radiotherapy, or
  • Desire to avoid surgery

Treatment with the Radixact System is an outpatient procedure that does not require incisions or general anesthesia. Most patients will not require hospitalization or a long recovery time.

Enabling re-treatment

Because the precise targeting of the Radixact System significantly reduces irradiation of surrounding healthy tissues, Radixact can be a powerful treatment option for a wider range of lung cancer patients, including patients who have previously undergone radiation or surgical procedures, and experience a recurrence.

An effective, less disruptive treatment option

The Radixact System, the next-generation TomoTherapy platform, maximizes radiation delivered to the target — while helping to minimize radiation dose to surrounding healthy tissues. The result is highly personalized treatment designed to significantly reduce the risk of the side effects that too often disrupt the lives of patients during and after treatment. The Radixact System is one of the most integrated, advanced systems for comprehensive cancer treatment available today, enabling precise delivery of treatments for the full spectrum of lung cancer patients — ranging from early-stage non-small cell lung cancer (NSCLC) to post-surgery treatment of mesothelioma.

Radixact treatment is an outpatient procedure that does not require incisions, or general anesthesia. Most patients will not require hospitalization or a long recovery period.

Find a Radixact Treatment Center

Share Your Radixact Story

Learn More About Radixact Treatment

References:

1 Rosen LR, Fischer-Valuck BW, Katz SR et. “Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.” Tumori. 2014 Jan-Feb;100(1):42-8. doi: 10.1700/1430.15814.

2 Arcangeli S, Falcinelli L, Bracci S et al. “Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours.” Br J Radiol. 2017 Mar;90(1071):20160853. doi: 10.1259/bjr.20160853.

3 Minatel E, Trovo M, Polesel J et al. “Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.” Lung Cancer. 2014 Jan;83(1):78-82. doi: 10.1016/j.lungcan.2013.10.013.

4 Sole CV, Lopez Guerra JL, Matute R et al. “Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases.” Clin Transl Oncol. 2013 Jun;15(6):484-91. doi: 10.1007/s12094-012-0956-2.

Share Your Story

Educating others about your experience with the Radixact® or TomoTherapy® System can help others who face similar decisions about their own cancer treatment choices.

If you are interested in sharing your story, please fill out the form below and an Accuray representative will contact you.

Privacy Disclaimer: To protect your safety, please do not provide your personal or sensitive information, such as your medical history, on our websites. By entering any information on our websites, you understand and agree that such information will be transferred to Accuray Incorporated in the United States. Please read our Privacy Policy.